M. Borzio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
M. Borzio has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
A. Salmi
Dipartimento Medicina, Università di Verona, Italy
5 shared publicationsG. Francica
Presidio Ospedaliero Pineta Grande – Unità di Ecointerventistica – Castelvolturno, Italy
5 shared publicationsR. Sacco
UO Gastroenterologia e Malattie del Ricambio, Azienda Ospedaliero Universitaria Pisana, Ospedale Cisanello, Pisa, Italy
5 shared publicationsA. Rossini
Dipartimento di Medicina, SSVD di Epatologia, ASST Spedali Civili di Brescia, Italy
4 shared publicationsE. Dionigi
UOC Gastroenterologia ed Endoscopia Digestiva, ASST Melegnano e della Martesana, Italy
4 shared publicationsF. Fornari
Unità di Gastroenterologia ed Epatologia, Ospedale G. da Saliceto, Piacenza, Italy
4 shared publications
Latest Publications
- 1 February 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (1) , e4
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study
- 1 February 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (1) , e4
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S454-S455
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S454-S455
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S272-S273
671 CLINICAL FEATURES OF NON ALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC) IN ITALY: A MULTICENTER PROSPECTIVE SURVEY
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S272-S273
671 CLINICAL FEATURES OF NON ALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC) IN ITALY: A MULTICENTER PROSPECTIVE SURVEY
- 1 February 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S44
F-44 Improving prognosis of HCC in the real-world clinical practice: an Italian field experience
- 1 February 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45, S44
F-44 Improving prognosis of HCC in the real-world clinical practice: an Italian field experience
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S141-S142
OC.10.6: EPAHCC STUDY: AN OPEN WINDOW OF THE “REAL WORLD” OF HCC IN ITALY
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S141-S142
OC.10.6: EPAHCC STUDY: AN OPEN WINDOW OF THE “REAL WORLD” OF HCC IN ITALY
- 28 February 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42, S3-3
6 EPIDEMIOLOGICAL CHANGES OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: A CURRENT CLINICAL PROBLEM
- 28 February 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42, S3-3
6 EPIDEMIOLOGICAL CHANGES OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: A CURRENT CLINICAL PROBLEM
- 1 February 2001
- Published by Elsevier in Digestive and Liver Disease
- Vol. 33 (1) , 41-48
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study
- 1 February 2001
- Published by Elsevier in Digestive and Liver Disease
- Vol. 33 (1) , 41-48
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study
- 1 June 1997
- Vol. 29 (3) , 262-6
Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.
Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic-resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 +/- 1.2 log CFU vs post treatment mean 9.6 +/- 0.5 log CFU, p < 0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Results of this study demonstrate the efficacy of oral ciprofloxacin as a selective intestinal decontaminant and ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-negative flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.
- 1 June 1997
- Vol. 29 (3) , 262-6
Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.
Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic-resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 +/- 1.2 log CFU vs post treatment mean 9.6 +/- 0.5 log CFU, p < 0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Results of this study demonstrate the efficacy of oral ciprofloxacin as a selective intestinal decontaminant and ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-negative flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.